Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Biotricity Inc. (NASDAQ:BTCY) announces the launch of its new Biokit, a personal medical device kit comprising an FDA-cleared digital thermometer, pulse oximeter, and blood pressure cuff. The kit aims to enhance remote cardiac monitoring and will be available in Q1 2022. These devices integrate with Biotricity's ecosystem, allowing real-time data sharing between patients and physicians. This launch is expected to expand the company's addressable market in the $18.4 billion North American portable medical device sector, aligning with Biotricity's goal to support cardiac patients effectively.
Biotricity, Inc. (NASDAQ:BTCY) announced a successful underwritten public offering, resulting in total gross proceeds of approximately $16 million. The offering, which closed on August 30, 2021, saw the underwriter partially exercise its option to purchase 382,331 additional shares, increasing the total shares sold to 5,382,331. This offering aligns with an effective shelf registration statement. H.C. Wainwright & Co. managed the offering, and it is aimed at advancing Biotricity's healthcare technology solutions.
Biotricity, Inc. (NASDAQ:BTCY) announced continued sales growth driven by the FDA-approved Bioflux mobile cardiac telemetry device, achieving a 290% year-over-year revenue increase in FY22-1Q and approximately 49% sequential growth. The company recently completed a $15 million equity raise and listed on the Nasdaq. CEO Waqaas Al-Siddiq will present at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand from September 13-15, 2021. The focus will be on sales expansion and product portfolio growth to enhance the total addressable market.
Biotricity, Inc. (NASDAQ:BTCY) has successfully closed an underwritten public offering, raising approximately $15 million by selling 5 million shares at $3.00 each. The underwriter has a 30-day option to buy an additional 750,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including working capital and potential acquisitions. This offering was conducted under an effective registration statement declared by the SEC. Biotricity focuses on remote health monitoring solutions for chronic care management.
Biotricity Inc. (BTCY) announced a public offering of 5,000,000 shares of common stock, priced at $3.00 per share, totaling approximately $15 million in gross proceeds. The offering includes a 30-day option for the underwriter to purchase an additional 750,000 shares. The closing is expected on August 30, 2021, with shares listed on the Nasdaq Capital Market as of August 26, 2021. H.C. Wainwright & Co. is the sole book-running manager. The shares are offered through a prospectus filed with the SEC.
Biotricity (OTCQB:BTCY) has announced plans for an underwritten public offering of its common stock as it prepares for a potential listing on the Nasdaq Capital Market. The offering will include a 30-day option for the underwriter to purchase additional shares. Funds raised will support general corporate purposes like working capital and acquisitions. The offering is subject to market conditions and is made under an effective shelf registration statement filed with the SEC.
Biotricity (OTCQB:BTCY) has reported impressive results for Q1 of fiscal 2022, marking a record revenue of $1.76 million, representing a 290% year-over-year growth, the ninth consecutive quarter of triple-digit growth. This also reflects a 49% sequential increase compared to the previous quarter. Operating expenses grew modestly by 17% to $4.2 million, indicating the scalability of their business model. The company awaits FDA approval for its new Biotres holter product, poised for a swift launch. Future revenue growth is projected as the company continues to expand its market presence.
Biotricity (OTCQB:BTCY) plans to release its financial results for the first quarter of fiscal 2022 on August 16, 2021, after market close. A conference call and live webcast will be held on the same day at 1:30 p.m. PT to discuss the results. Investors can access the call at +1 334-777-6978 or 800-367-2403 using the passcode 7356128. For online access, a link will be available on their website. The company focuses on remote monitoring and chronic care management in healthcare.
Biotricity, Inc. (OTCQB:BTCY) announced preliminary revenue guidance for its fiscal Q1 2022, indicating a record growth quarter. The company expects a revenue increase of over 45% from the prior quarter and more than 280% year-over-year, marking its 9th consecutive quarter of growth. Management anticipates adding new cardiology customers quarterly, expanding from 17 to 23 states. Despite potential pandemic impacts, the company expects continued triple-digit revenue growth for the remainder of the year.
Biotricity, Inc. (OTCQB:BTCY) reported strong financial results for Q4 and fiscal year 2021, with Q4 revenue reaching $1.2 million, reflecting an 8th consecutive quarter of triple-digit year-over-year growth. This quarter saw a 227% increase in revenue, surpassing the previous quarter's 162%. The annual revenue totaled $3.4 million, up 139% from fiscal 2020. Despite a net loss of $16.2 million, management anticipates further growth, targeting triple-digit revenue increases for fiscal 2022.
FAQ
What is the current stock price of BIOTRICITY (BTCY)?
What is the market cap of BIOTRICITY (BTCY)?
What is Biotricity, Inc.?
What are some of Biotricity's products?
What is the vision of Biotricity, Inc.?
How does Biotricity contribute to the healthcare industry?
